Graft-versus-host disease in mini-transplant

Leukemia & Lymphoma
Shin Mineishi, Friedrich G Schuening

Abstract

Mini-transplant has been used popularly in recent years. The intensity of conditioning regimens is less in mini-transplant, thus the anti-tumor effect is mainly carried by an immunological reaction, called graft-versus-leukemia (GVL)/graft-versus-tumor (GVT) effect. Thus, graft-versus-host disease (GVHD) in mini-transplant has drawn much attention as a surrogate marker for GVL/GVT effect. However, as the regimen-related toxicity is less in mini-transplant, it is also true that GVHD is the single most worrisome adverse event after mini-transplant. As opposed to early predictions, the incidence and severity of GVHD after mini-transplant does not seem to be much different from the one after conventional stem cell transplant (CST). In addition, researchers find that host antigen presenting cells (APC) may play an important role in the development of GVHD, and thus the existence of donor-host chimerism may be critical. As a result, the theory regarding GVHD after mini-transplant is getting more confusing. A comprehensive understanding of GVHD after mini-transplant is necessary.

References

May 10, 1979·The New England Journal of Medicine·P L WeidenR Storb
Mar 7, 1991·The New England Journal of Medicine·J L Ferrara, H J Deeg
Jun 18, 1981·The New England Journal of Medicine·P L WeidenUNKNOWN Seattle Marrow Transplant Team
Feb 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R H CollinsJ Nemunaitis
Feb 13, 2001·British Journal of Haematology·O RingdénUNKNOWN Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation
May 15, 2001·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·A E Patterson, R Korngold
Jan 5, 2002·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·A ShimoniS Giralt
Jan 12, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John E LevineRobert H Collins
Apr 17, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian I RiniNicholas J Vogelzang
Jun 4, 2002·Nature Medicine·Takanori TeshimaJames L M Ferrara
Sep 28, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Katharine BransonStephen Mackinnon
Oct 18, 2002·Blood·José A Pérez-SimónUNKNOWN Spanish and United Kingdom Collaborative Groups for Nonmyeloablative Transplantation
Apr 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hartmut BertzJürgen Finke
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J ScheteligUNKNOWN Cooperative German Transplant Study Group
Aug 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D C TaussigM J Barnett

❮ Previous
Next ❯

Citations

Jul 28, 2012·Stem Cell Reviews and Reports·S Abdul Wahid Fadilah, Md Pazil Aqilah
Nov 9, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Domenico PastoreGiorgina Specchia

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.